Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRC 253

Next Previous
Drug Profile

TRC 253

Alternative Names: JNJ 63576253; TRC-253

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; TRACON Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Ethers; Fluorinated hydrocarbons; Nitriles; Organic sulfur compounds; Picolines; Piperidines; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 12 Nov 2024 Discontinued - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (TRACON Pharmaceuticals website, March 2025)
  • 22 Mar 2021 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (TRACON Pharmaceuticals pipeline, March 2021)
  • 30 Sep 2020 TRC 253 is still in phase I/II trial for Prostate cancer in USA (NCT02987829)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top